US Stock MarketDetailed Quotes

PDLI PDL BioPharma

Watchlist
  • 0.000
  • 0.0000.00%
Close Jul 15 09:30 ET
0Market Cap0.00P/E (TTM)

About PDL BioPharma Company

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Company Profile

SymbolPDLI
Company NamePDL BioPharma
CEOMr. Dominique Monnet
MarketNASDAQ
Employees75
Securities TypeOrdinary Shares
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Dominique Monnet
  • Director, Chief Executive Officer and President
  • --
  • Edward Imbrogno
  • Vice President and Chief Financial Officer
  • --
  • Christopher L. Stone
  • Vice President, General Counsel and Secretary
  • --
  • Elizabeth G. O’Farrell
  • Chairman of the Board
  • --
  • John P. Mclaughlin
  • Director
  • --
  • Alan L. Bazaar
  • Independent Director
  • --
  • Natasha A. Hernday
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg